

# GenBody COVID-19 Antigen Rapid Test Kit Anterior Nasal Swab

For Point of Care

Rapid detection of SARS-CoV-2 will play a key role in the global spread of the virus.

Affordable and sensitive test that does not require an additional reader, with a processing time of 15-20 minutes.

For use under an Emergency Use Authorization (EUA) Only For in vitro diagnostic use only For professional use only







#### **Features**

- Detects SARS-CoV-2 nucleocapsid protein antigen
- Rapid results in 15-20 minutes
- Anterior nasal swab specimen collection
- Identifies acute infection with a 92.31% sensitivity and 99.04% specificity
- For use in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.
- The confirmed LoD for the GenBody COVID-19
  Ag is 1.11 x 10<sup>2</sup> TCID50/mL.

#### **Our Competitive Advantage**

- Large manufacturing capacity and immediately available for distribution
- Global sales and regulatory approval throughout Europe, Asia and South America
- Selected by NIH for the Rapid Acceleration of Diagnostics program, for the US production of the GenBody COVID-19 Ag test.
- Made in the USA (Q4 2021) and South Korea
- The GenBody COVID-19 Ag test detects the Sars-CoV-2 variants.

The GenBody COVID-19 Ag is an immunochromatographic rapid diagnostic test (RDT) intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab (NP) or anterior nasal (AN) specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first six days of symptom onset. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. \$263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Accreditation.






#### **Procedure**


01

**Add** the Extraction solution to the **Fill Line** indicated on the Extraction Tube




02

Collect anterior nasal swab specimen.



03

Insert the collected specimen swab into the Extraction Solution. Mix by squeezing the tube and simultaneously rotating the swab 8~10 times. Place the Dropper Tip



04

Place test device on a **level** surface. Add 4 drops of the solution to the sample well.




#### **Result Interpretation**

Read the results between **15-20** minutes.

Do not read after 20 minutes.








SARS-CoV-2 antigen present does not rule out co-infection with other pathogens. The color intensity in the test region will vary depending on the amount of SARS-CoV-2 antigen present in the sample. Any faint colored line(s) in the test region(s) should be considered as positive

#### **Negative**



Negative test results do not preclude infection and should not be used as the sole basis for treatment or other patient management decisions, including infection control decisions. It is recommended that these results be conrmed by a molecular testing method, if necessary for patientmanagement.

#### Invalid



Re-run the test one time using the remaining specimen in the extraction vial if an invalid result is obtained during initial testing.

### **GenBody COVID-19 Ag Kit**



25 tests / kit

- 25 Single Use Test Devices Individually Foil-Pouched
- 2 Bottles of Extraction Solution
- 25 Single Use Extraction Tubes
- 25 Single Use Dropper Tips
- 25 Sterilized anterior nasal swabs

Between 35.6 to 86 degrees Fahrenheit

12 months from the date of manufacture

COVAG025-NU











## GenBody COVID-19 Performance Comparison

(Visually Read Tests)

Company	Product Name	Sensitivity	Specificity	Limit of Detection (TCID <sub>50</sub> /mL)
GenBody Inc	GenBody COVID-19 Ag	92.31%	99.04%	1.11 X 10 <sup>2</sup>
Salofa Oy	Sienna-Clarity COVID-19 Antigen Rapid Test Cassette	87.50%	98.90%	1.25 X 10 <sup>3</sup>
Inbios International	SCoV-2 Ag Detect Rapid Test	86.67%	100.00%	6.3 X 10 <sup>3</sup>
Access Bio Inc	CareStart COVID-19 Antigen test	87.18%	100.00%	8 X 10 <sup>2</sup>
Quidel Corp	QuickVue SARS Antigen Test	96.60%	99.30%	7.57 X 10 <sup>3</sup>
Abbott Diagnostics	BinaxNOW COVID-19 Ag Card	84.60%	98.50%	140.6
Orasure Technologies	InteliSwab COVID-19 Rapid Test Pro	84.40%	98.00%	2.5 X 10 <sup>2</sup>
Phase Scientific	INDICAID COVID-19 Rapid Antigen Test	84.40%	96.80%	140 TCID <sub>50</sub> per Swab





